Skip to content
Catalyst

menaquinone-7What was measured

Measured, with no finding

417 endpoints

Show what was measuredHide what was measured
  • bone markers and coagulation parameters

    no effect

    In both groups, bone markers and coagulation parameters remained constant over time

    PMID 19450370 · one of two readings recorded this

  • circulating undercarboxylated osteocalcin, carboxylated osteocalcin, ucOC:cOC ratio and serum MK-7 in healthy prepubertal children

    decreases, n = 28

    Not recorded as a finding: the result compares a group with itself, not with a control

    In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.

    PMID 19450370 · one of two readings recorded this

  • circulating undercarboxylated osteocalcin (ucOC), carboxylated osteocalcin and ucOC:cOC ratio, serum, 8 weeks

    decreases, n = 28

    Not recorded as a finding: the result compares a group with itself, not with a control

    In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.

    PMID 19450370 · one of two readings recorded this

  • serum ucOC, UCR and MK-7 concentration

    modulates, n = 28

    In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased

    PMID 19450370 · one of two readings recorded this

  • serum undercarboxylated and carboxylated osteocalcin (ucOC:cOC ratio) and serum MK-7 concentration

    increases, MK-7 supplementation increased circulating MK-7 and osteocalcin carboxylation

    Not recorded as a finding: this platform holds no node for the endpoint

    These findings demonstrate that in healthy, prepubertal children, modest supplementation with MK-7 increases circulating concentrations of MK-7 and increases osteocalcin carboxylation.

    PMID 19450370 · one of two readings recorded this

  • serum undercarboxylated osteocalcin, carboxylated osteocalcin and ucOC:cOC ratio (UCR) in healthy prepubertal children

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.

    PMID 19450370 · one of two readings recorded this

  • ucOC, cOC, UCR and MK-7

    no effect

    Within the placebo group, ucOC, cOC, UCR and MK-7 did not significantly change over time

    PMID 19450370 · one of two readings recorded this

  • bone loss rate (bone mineral density change), femoral neck

    no effect

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone loss rate (bone mineral density change), lumbar spine

    no effect

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone loss rate (bone mineral density change), total body

    no effect

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone loss rate (bone mineral density change), total hip

    no effect

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone mineral density change (bone loss rate), femoral neck, 12 months; instrument not named in abstract

    no effect

    Not recorded as a finding: CAT:outcome/femoral-neck-bmd exists, but the result sentence covers the femoral neck only as 'any other measurement site', so no object span names it; the node also requires DXA, which the abstract never states

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone mineral density change (bone loss rate), lumbar spine, 12 months; instrument not named in abstract

    no effect

    Not recorded as a finding: CAT:outcome/lumbar-spine-bmd exists, but the result sentence covers the lumbar spine only as 'any other measurement site', so no object span names it; the node also requires DXA and states vertebral levels, neither given in the abstract

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone mineral density change (bone loss rate), total body, 12 months; instrument not named in abstract

    no effect

    Not recorded as a finding: no outcome node for total-body BMD; the result sentence names it only as 'any other measurement site'

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • bone mineral density change (bone loss rate), total hip, 12 months; instrument not named in abstract

    no effect

    Not recorded as a finding: no outcome node for total hip BMD; the only result sentence also does not name the compound, only 'between the groups'

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • carboxylated osteocalcin (cOC)

    increases, p = 0.001

    Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).

    PMID 19937427 · one of two readings recorded this

  • femoral neck bone mineral density, rate of bone loss over 12 months

    no effect

    Not recorded as a finding: CAT:outcome/femoral-neck-bmd exists, but the only between-group sentence names the total hip and 'any other measurement site'; femoral neck is not in that sentence, so the object span cannot be anchored without a second (measurement-site) sentence. The abstract also does not state the DXA scanner the node records

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • lumbar spine bone mineral density, rate of bone loss over 12 months

    no effect

    Not recorded as a finding: CAT:outcome/lumbar-spine-bmd exists, but the only between-group sentence names the total hip and 'any other measurement site'; lumbar spine is not in that sentence, so the object span cannot be anchored without a second (measurement-site) sentence. Vertebral levels are not stated in the abstract

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • serum carboxylated osteocalcin (cOC), assay not named in abstract

    increases

    Not recorded as a finding: no outcome node: CAT:outcome/serum-undercarboxylated-osteocalcin covers the undercarboxylated fraction only; no node for carboxylated osteocalcin

    Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).

    PMID 19937427 · one of two readings recorded this

  • serum carboxylated osteocalcin (cOC)

    increases

    Not recorded as a finding: no outcome node for carboxylated osteocalcin; CAT:outcome/serum-undercarboxylated-osteocalcin is the undercarboxylated form only, a different analyte

    Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).

    PMID 19937427 · one of two readings recorded this

  • total body bone mineral density, rate of bone loss over 12 months

    no effect

    Not recorded as a finding: no outcome node for total body BMD; and the sentence covers it only as 'any other measurement site'

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • total hip bone mineral density, rate of bone loss over 12 months

    no effect

    Not recorded as a finding: no outcome node for total hip BMD; CAT:outcome/femoral-neck-bmd is the femoral neck region of interest only, a different site

    After 12 months, there were no statistical differences in bone loss rates between the groups at the total hip or any other measurement site.

    PMID 19937427 · one of two readings recorded this

  • under-carboxylated osteocalcin (ucOC)

    decreases, p = 0.001

    Serum levels of cOC increased and ucOC decreased in the treatment versus the placebo group (p < 0.001).

    PMID 19937427 · one of two readings recorded this

  • L2 to L4 bone mineral content

    no effect, p = 0.5

    the difference between vitamin K2 and placebo for the lumbar spine (L2-L4) bone mineral density (BMD) was 0.028 (SE 0.014) g/cm(2), P=0.055 and for L2 to L4 bone mineral content was 1.33 (SE 1.91) g/cm(2) (P=0.5)

    PMID 20177349 · one of two readings recorded this

  • L2 to L4 bone mineral content

    no effect, p = 0.9

    In lung recipients separately, the difference for bone mineral content was 3.39 g (SE 1.65), P=0.048 and in heart recipients 0.45 (SE 0.02) g, P=0.9 after controlling for baseline measures.

    PMID 20177349 · one of two readings recorded this

  • L2 to L4 bone mineral content

    increases, p = 0.048

    In lung recipients separately, the difference for bone mineral content was 3.39 g (SE 1.65), P=0.048 and in heart recipients 0.45 (SE 0.02) g, P=0.9 after controlling for baseline measures.

    PMID 20177349 · one of two readings recorded this

  • lumbar spine (L2-L4) bone mineral density

    increases, p = 0.019

    fitted to model differences in the L2 to L4 BMD, controlled for possible confounding variables (including use of bisphosphonate), and the only significant predictors were organ (B=-0.065 g/cm(2), P<0.001) and vitamin K2 (B=0.034 g/cm(2), P=0.019)

    PMID 20177349 · one of two readings recorded this

  • lumbar spine (L2-L4) bone mineral density

    increases, p = 0.055

    In all recipients, 1 year after solid organ transplantation, the difference between vitamin K2 and placebo for the lumbar spine (L2-L4) bone mineral density (BMD) was 0.028 (SE 0.014) g/cm(2), P=0.055

    PMID 20177349 · one of two readings recorded this

  • lumbar spine (L2-L4) bone mineral density

    unclear, p = 0.001

    fitted to model differences in the L2 to L4 BMD, controlled for possible confounding variables (including use of bisphosphonate), and the only significant predictors were organ (B=-0.065 g/cm(2), P<0.001) and vitamin K2 (B=0.034 g/cm(2), P=0.019)

    PMID 20177349 · one of two readings recorded this

  • parathyroid hormone

    increases

    Insufficient vitamin D status was common, and the parathyroid hormone was highest in the K2 group indicating a higher need for vitamin D.

    PMID 20177349 · one of two readings recorded this

  • carboxylation of circulating matrix Gla-protein (dp-ucMGP)

    increases

    MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP

    PMID 22289649 · one of two readings recorded this

  • carboxylation of circulating osteocalcin and matrix Gla protein (ucOC, cOC, dp-ucMGP by ELISA; ucOC:cOC ratio) and thrombin generation by calibrated automated thrombography

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.

    PMID 22289649 · one of two readings recorded this

  • carboxylation of circulating osteocalcin and matrix Gla protein (ucOC:cOC ratio, desphospho-uncarboxylated MGP), ELISA

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.

    PMID 22289649 · one of two readings recorded this

  • carboxylation of circulating osteocalcin and matrix Gla protein (ucOC:cOC ratio, dp-ucMGP by ELISA); endogenous thrombin potential and peak height by calibrated automated thrombography

    increases, increased carboxylation of circulating OC and MGP at doses around the RDA

    Not recorded as a finding: this platform holds no node for the endpoint

    MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.

    PMID 22289649 · one of two readings recorded this

  • carboxylation of circulating osteocalcin and matrix Gla protein (ucOC:cOC ratio, dp-ucMGP), ELISA; endogenous thrombin potential by calibrated automated thrombography

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP.

    PMID 22289649 · one of two readings recorded this

  • carboxylation of circulating osteocalcin (ucOC:cOC ratio)

    increases

    MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP

    PMID 22289649 · one of two readings recorded this

  • endogenous thrombin potential and peak height

    no effect

    No adverse effects on thrombin generation were observed

    PMID 22289649 · one of two readings recorded this

  • change in serum 25(OH)D

    increases, p = 0.01

    The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively)

    PMID 22392526 · one of two readings recorded this

  • change in serum IGF-I

    increases, p = 0.028

    The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively)

    PMID 22392526 · one of two readings recorded this

  • lumbar spine BMD

    increases, p = 0.05

    significant increases in lumbar spine BMD were observed only for CaDK1 and CaDK2 compared to CG (P < 0.05)

    PMID 22392526 · one of two readings recorded this

  • serum IGF-I, serum 25(OH)D, lumbar spine and total-body BMD, ucOC/OC ratio, urine deoxypyridinoline

    increases, p = 0.028

    Not recorded as a finding: the intervention held more than the compound

    The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively).

    PMID 22392526 · one of two readings recorded this

  • serum undercarboxylated osteocalcin to osteocalcin ratio

    decreases, p = 0.001

    both the CaDK1 and CaDK2 groups had a significantly lower mean serum undercarboxylated osteocalcin to osteocalcin ratio and urine deoxypyridinoline levels at follow-up compared to the CaD and CG groups (P = 0.001 and P = 0.047, respectively)

    PMID 22392526 · one of two readings recorded this

  • total-body BMD

    increases, p = 0.05

    Significant increases in total-body BMD were observed in all intervention groups compared to CG (P < 0.05)

    PMID 22392526 · one of two readings recorded this

  • urine deoxypyridinoline

    decreases, p = 0.047

    both the CaDK1 and CaDK2 groups had a significantly lower mean serum undercarboxylated osteocalcin to osteocalcin ratio and urine deoxypyridinoline levels at follow-up compared to the CaD and CG groups (P = 0.001 and P = 0.047, respectively)

    PMID 22392526 · one of two readings recorded this

  • circulating desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) by ELISA

    decreases, 31% at 180 ug and 46% at 360 ug after 12 weeks; unchanged on placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively, while dp-ucMGP levels remained unchanged after placebo treatment.

    PMID 23062766 · one of two readings recorded this

  • circulating desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), ELISA

    decreases, 31% and 46% decrease at 180 and 360 μg

    Not recorded as a finding: this platform holds no node for the endpoint

    Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively, while dp-ucMGP levels remained unchanged after placebo treatment.

    PMID 23062766 · one of two readings recorded this

  • desphospho-carboxylated MGP and total uncarboxylated MGP, ELISA

    no effect

    Not recorded as a finding: no outcome node for dp-cMGP or t-ucMGP; sentence is agentless

    Changes over time of dp-cMGP (p = 0.42) and t-ucMGP (p = 0.23) levels did not differ between treatment arms.

    PMID 23062766 · one of two readings recorded this

  • desphospho-carboxylated MGP (dp-cMGP)

    no effect, p = 0.42

    Changes over time of dp-cMGP (p = 0.42) and t-ucMGP (p = 0.23) levels did not differ between treatment arms

    PMID 23062766 · one of two readings recorded this

  • desphospho-uncarboxylated MGP (dp-ucMGP)

    decreases, p = 0.001

    Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively

    PMID 23062766 · one of two readings recorded this

  • desphospho-uncarboxylated MGP (dp-ucMGP)

    decreases, p = 0.001

    Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively

    PMID 23062766 · one of two readings recorded this

  • desphospho-uncarboxylated MGP (dp-ucMGP)

    no effect

    while dp-ucMGP levels remained unchanged after placebo treatment

    PMID 23062766 · one of two readings recorded this

  • osteocalcin ratio ucOC:cOC, circulating, assay not stated

    decreases, 60% at 180 μg, 74% at 360 μg

    Not recorded as a finding: no outcome node for the ucOC:cOC ratio

    The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001), while levels remained unchanged after placebo treatment.

    PMID 23062766 · one of two readings recorded this

  • other cardiovascular risk factors

    no effect

    Other cardiovascular risk factors did not differ between treatments arms

    PMID 23062766 · one of two readings recorded this

  • ratio of uncarboxylated osteocalcin to carboxylated osteocalcin (ucOC:cOC), proxy of vitamin K status

    decreases, 60% (180 μg) and 74% (360 μg) decrease

    Not recorded as a finding: No outcome node for the ucOC/cOC ratio.

    The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001), while levels remained unchanged after placebo treatment.

    PMID 23062766 · one of two readings recorded this

  • total uncarboxylated MGP (t-ucMGP)

    no effect, p = 0.23

    Changes over time of dp-cMGP (p = 0.42) and t-ucMGP (p = 0.23) levels did not differ between treatment arms

    PMID 23062766 · one of two readings recorded this

  • ucOC/cOC ratio

    decreases, p = 0.001

    The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001)

    PMID 23062766 · one of two readings recorded this

  • ucOC/cOC ratio

    decreases, p = 0.001

    The osteocalcin ratio also decreased significantly after 12-week supplementation with 180 μg (60%) and 360 μg (74%) MK-7 (P time*treatment < 0.001)

    PMID 23062766 · one of two readings recorded this

  • serum MK-4 level after 7 days consecutive administration

    no effect

    Consecutive administration of MK-4 (60 μg; 135 nmol) or MK-7 (60 μg; 92 nmol) for 7 days demonstrated that MK-4 supplementation did not increase serum MK-4 levels

    PMID 23140417 · one of two readings recorded this

  • serum MK-4 level after single dose

    no effect

    MK-4 was not detectable in the serum of all subjects at any time point

    PMID 23140417 · one of two readings recorded this

  • serum MK-7 level after 7 days consecutive administration

    increases

    However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects

    PMID 23140417 · one of two readings recorded this

  • serum MK-7 level after single and 7-day oral dosing, compared with MK-4

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects.

    PMID 23140417 · one of two readings recorded this

  • serum MK-7 level after single dose and after 7 days of consecutive administration, compared with MK-4

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    However, consecutive administration of MK-7 increased serum MK-7 levels significantly in all subjects.

    PMID 23140417 · one of two readings recorded this

  • bone mineral content and density, femoral neck

    increases

    MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip

    PMID 23525894 · one of two readings recorded this

  • bone mineral content and density, lumbar spine

    increases

    MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip

    PMID 23525894 · one of two readings recorded this

  • bone mineral content and density, total hip

    no effect

    MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip

    PMID 23525894 · one of two readings recorded this

  • femoral neck bone strength indices

    increases

    Bone strength was also favorably affected by MK-7

    PMID 23525894 · one of two readings recorded this

  • loss in vertebral height, lower thoracic region mid-site

    decreases

    MK-7 significantly decreased the loss in vertebral height of the lower thoracic region at the mid-site of the vertebrae

    PMID 23525894 · one of two readings recorded this

  • vitamin K status (ucOC/cOC ratio)

    increases

    MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip

    PMID 23525894 · one of two readings recorded this

  • desphosphorylated-uncarboxylated matrix Gla protein (dp-uc-MGP), baseline and after 8 weeks, in chronic haemodialysis patients given MK-7 360, 720 or 1080 µg thrice weekly

    decreases

    Not recorded as a finding: the comparison was against another active treatment

    MK-7 supplementation dose dependently reduced dp-uc-MGP.

    PMID 24285428 · one of two readings recorded this

  • desphosphorylated-uncarboxylated MGP (dp-uc-MGP) at baseline and after 8 weeks of MK-7 360, 720 or 1080 µg thrice weekly (assay not named in the abstract)

    decreases, dose-dependent reduction of dp-uc-MGP; no MK-7-free arm (dose-versus-dose design)

    Not recorded as a finding: the comparison was against another active treatment

    MK-7 supplementation dose dependently reduced dp-uc-MGP.

    PMID 24285428 · one of two readings recorded this

  • dp-uc-MGP

    decreases

    MK-7 supplementation dose dependently reduced dp-uc-MGP.

    PMID 24285428 · one of two readings recorded this

  • dp-uc-MGP

    decreases, p = 0.023

    At baseline, dp-uc-MGP was not associated with phylloquinone intake (P = 0.92), but correlated inversely with menaquinone intake (P = 0.023).

    PMID 24285428 · one of two readings recorded this

  • dp-uc-MGP

    no effect, p = 0.92

    At baseline, dp-uc-MGP was not associated with phylloquinone intake (P = 0.92), but correlated inversely with menaquinone intake (P = 0.023).

    PMID 24285428 · one of two readings recorded this

  • dp-uc-MGP

    decreases

    The levels decreased by 17, 33 and 46% in the respective groups.

    PMID 24285428 · one of two readings recorded this

  • dp-uc-MGP

    decreases

    The levels decreased by 17, 33 and 46% in the respective groups.

    PMID 24285428 · one of two readings recorded this

  • dp-uc-MGP

    decreases

    The levels decreased by 17, 33 and 46% in the respective groups.

    PMID 24285428 · one of two readings recorded this

  • acute phase markers (IL-6, hsCRP, TNF-α) and endothelial dysfunction markers (VCAM, E-selectin, AGEs)

    no effect

    MK-7 decreased dp-ucMGP by 50 % compared to placebo, but did not influence the markers for acute phase and endothelial dysfunction

    PMID 25694037 · one of two readings recorded this

  • carotid-femoral pulse wave velocity (cfPWV)

    decreases

    After three year MK-7 supplementation cfPWV and the Stiffness Index βsignificantly decreased in the total group

    PMID 25694037 · one of two readings recorded this

  • circulating dp-ucMGP

    decreases

    MK-7 decreased dp-ucMGP by 50 % compared to placebo, but did not influence the markers for acute phase and endothelial dysfunction

    PMID 25694037 · one of two readings recorded this

  • distension, compliance, distensibility, Young's Modulus and local carotid PWV (cPWV)

    increases

    distension, compliance, distensibility, Young's Modulus, and the local carotid PWV (cPWV) improved in women having a baseline Stiffness Index β above the median of 10.8

    PMID 25694037 · one of two readings recorded this

  • Stiffness Index β

    decreases

    After three year MK-7 supplementation cfPWV and the Stiffness Index βsignificantly decreased in the total group

    PMID 25694037 · one of two readings recorded this

  • C-reactive protein (CRP)

    decreases

    a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found

    PMID 26073022 · one of two readings recorded this

  • DAS28-ESR, C-reactive protein, ESR, ucOC and MMP-3 in RA patients

    decreases

    Not recorded as a finding: the result compares a group with itself, not with a control

    In the cross sectional study, a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found.

    PMID 26073022 · one of two readings recorded this

  • disease activity score assessing 28 joints with ESR (DAS28-ESR)

    decreases

    a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found

    PMID 26073022 · one of two readings recorded this

  • erythrocyte sedimentation rate, DAS28-ESR, C-reactive protein, MMP-3 and undercarboxylated osteocalcin in RA patients

    decreases, significant decrease in MK-7 treated group

    Not recorded as a finding: the result compares a group with itself, not with a control

    In the cross sectional study, a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found.

    PMID 26073022 · one of two readings recorded this

  • erythrocyte sedimentation rate (ESR)

    decreases

    a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found

    PMID 26073022 · one of two readings recorded this

  • matrix metalloproteinase-3 (MMP-3)

    decreases

    a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found

    PMID 26073022 · one of two readings recorded this

  • serum MK-7 level

    increases

    A marked increase in the levels of MK-7 for the moderate and good responders compared to non-responders was observed

    PMID 26073022 · one of two readings recorded this

  • ucOC, ESR and DAS28-ESR decrease

    decreases

    a marked decrease in RA clinical and biochemical markers for moderate and good response compared to non-responders was observed in ucOC, ESR and DAS28-ESR

    PMID 26073022 · one of two readings recorded this

  • undercarboxylated osteocalcin (ucOC)

    decreases

    a significant decrease in MK-7 treated group for the levels of undercarboxylated osteocalcin (ucOC), erythrocyte sedimentation rate (ESR), disease activity score assessing 28 joints with ESR (DAS28-ESR), C-reactive protein (CRP) and matrix metalloproteinase (MMP-3) was found

    PMID 26073022 · one of two readings recorded this

  • carboxylated osteocalcin/undercarboxylated osteocalcin ratio, circulating, dose-dependent increase in Study 1

    increases

    Not recorded as a finding: No outcome node for the cOC/ucOC ratio; ucOC concentration node does not cover a ratio.

    Menaquinone-7 increased the carboxylated osteocalcin/undercarboxylated osteocalcin ratio dose dependently, and significant effects were observed in both the 100 and 200 μg groups compared with the 0 μg group.

    PMID 26875489 · one of two readings recorded this

  • carboxylated osteocalcin/undercarboxylated osteocalcin ratio

    increases

    Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2)

    PMID 26875489 · one of two readings recorded this

  • carboxylated osteocalcin/undercarboxylated osteocalcin ratio

    increases

    Menaquinone-7 increased the carboxylated osteocalcin/undercarboxylated osteocalcin ratio dose dependently, and significant effects were observed in both the 100 and 200 μg groups compared with the 0 μg group

    PMID 26875489 · one of two readings recorded this

  • carboxylated osteocalcin/undercarboxylated osteocalcin ratio

    decreases

    The carboxylated osteocalcin/undercarboxylated osteocalcin ratio decreased significantly from baseline in the 0 μg menaquinone-7 group

    PMID 26875489 · one of two readings recorded this

  • carboxylated/undercarboxylated osteocalcin ratio, circulating, assay not stated

    increases

    Not recorded as a finding: no outcome node for the cOC/ucOC ratio

    Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2).

    PMID 26875489 · one of two readings recorded this

  • circulating carboxylated osteocalcin and undercarboxylated osteocalcin, and their cOC/ucOC ratio

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2).

    PMID 26875489 · one of two readings recorded this

  • circulating carboxylated osteocalcin / undercarboxylated osteocalcin ratio

    increases, dose dependent; significant at 100 and 200 ug vs 0 ug

    Not recorded as a finding: this platform holds no node for the endpoint

    Menaquinone-7 increased the carboxylated osteocalcin/undercarboxylated osteocalcin ratio dose dependently, and significant effects were observed in both the 100 and 200 μg groups compared with the 0 μg group.

    PMID 26875489 · one of two readings recorded this

  • undercarboxylated osteocalcin concentration

    decreases

    Undercarboxylated osteocalcin concentrations decreased significantly, and the carboxylated osteocalcin/undercarboxylated osteocalcin ratio increased significantly in the 100 μg menaquinone-7 group compared with the placebo group (Study 2)

    PMID 26875489 · one of two readings recorded this

  • circulating dp-ucMGP

    decreases

    Circulating dp-ucMGP and ucOC were significantly lowered after consumption of the yogurt products and the MK-7 capsules, reflecting vitamin K status improvement

    PMID 26908424 · one of two readings recorded this

  • circulating ucOC

    decreases

    Circulating dp-ucMGP and ucOC were significantly lowered after consumption of the yogurt products and the MK-7 capsules, reflecting vitamin K status improvement

    PMID 26908424 · one of two readings recorded this

  • fasting plasma concentrations of various biomarkers, yogurt K versus yogurt Kplus

    no effect

    No significant differences in fasting plasma concentrations of various biomarkers between the yogurts were found

    PMID 26908424 · one of two readings recorded this

  • increase in fasting plasma MK-7

    increases

    The increase in plasma MK-7 with the yogurt Kplus product was more pronounced than the increase in MK-7 with the capsules

    PMID 26908424 · one of two readings recorded this

  • bone mineral density at any site (DXA)

    no effect

    There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site

    PMID 27625301 · one of two readings recorded this

  • HRpQCT-derived parameters at the radius

    no effect

    There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site

    PMID 27625301 · one of two readings recorded this

  • tibia trabecular number percent change (HRpQCT)

    no effect

    trabecular number in tibia was unchanged in the MK-7-group (-0.1 ± 1.9%) (mean ± s.d.) and decreased in the placebo group (-3.5 ± 2.2%)

    PMID 27625301 · one of two readings recorded this

  • tibia trabecular spacing percent change (HRpQCT)

    no effect

    trabecular spacing was unchanged in the MK-7 group (+1.2 ± 8.0%) and increased in the placebo group (+4.5 ± 9.7%)

    PMID 27625301 · one of two readings recorded this

  • tibia trabecular thickness percent change (HRpQCT)

    no effect, p = 0.05

    trabecular thickness was unchanged in the MK-7 group (+0.2 ± 1.7%) and increased in the placebo group (+4.0 ± 2.2%) (between-group changes for all: P < 0.05)

    PMID 27625301 · one of two readings recorded this

  • tibial trabecular number, spacing and thickness by HRpQCT after 12 months in postmenopausal women with osteopenia

    Not recorded as a finding: this platform holds no node for the endpoint

    There were no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site.

    PMID 27625301 · one of two readings recorded this

  • undercarboxylated osteocalcin (ucOC) percent change

    decreases, p = 0.01

    ucOC decreased in the MK-7 group (-65.6 (59.1; 71.0) %) (median (CI)) compared with the placebo group (-6.4 (-13.5; 1.2) %) after 3 months (P < 0.01)

    PMID 27625301 · one of two readings recorded this

  • heart-rate AUC

    increases, p = 0.07

    Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.

    PMID 28646812 · one of two readings recorded this

  • maximal cardiac output during a graded cycle-ergometer exercise test, noninvasive skin-electrode cardiac output monitor; heart-rate and stroke-volume area under the curve

    increases, 12% increase in maximal cardiac output with vitamin K2 vs rice-flour placebo, P = .031, p = 0.031

    Not recorded as a finding: the paper never mentions the compound

    Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.

    PMID 28646812 · one of two readings recorded this

  • maximal cardiac output during a graded cycle ergometer test, noninvasive cardiac output from skin-mounted electrodes; also heart-rate AUC and stroke volume

    increases, 12% increase in maximal cardiac output, P = .031, p = 0.031

    Not recorded as a finding: the paper never mentions the compound

    Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.

    PMID 28646812 · one of two readings recorded this

  • maximal cardiac output

    increases, p = 0.031

    Vitamin K2 supplementation was associated with a 12% increase in maximal cardiac output, with P = .031, with a trend toward an increase in heart-rate AUC, with P = .070.

    PMID 28646812 · one of two readings recorded this

  • stroke volume

    no effect

    No significant changes occurred in stroke volume.

    PMID 28646812 · one of two readings recorded this

  • adherence (tablet count)

    no effect, p = 0.05

    No significant difference in adherence was found between groups: 90% (SD = 20) in the 200 μg vitamin K group, 82% (SD = 27) in the 400 μg vitamin K group, and 88% (SD = 33) in the placebo group (P >.05 for all comparisons).

    PMID 31211416 · one of two readings recorded this

  • adverse events (any), 200 µg arm versus placebo and 400 µg arms

    increases, more adverse events in the 200 µg arm than in the placebo or 400 µg arms

    Not recorded as a finding: Reported for one dose arm only, with no proportion or test in the text (supplement only), so it is not a whole-trial estimate for CAT:outcome/supplement-adverse-event-incidence.

    There were more adverse events in the 200‐μg arm than in the placebo or 400‐μg arms as shown in Supplementary Material S1.

    PMID 31211416 · one of two readings recorded this

  • adverse events (gastrointestinal events and injuries)

    more adverse events in the 200 µg arm than in the placebo or 400 µg arms

    Not recorded as a finding: A dose stratum only (200 µg) with no statistical test in the text, and it counts events where supplement-adverse-event-incidence needs the proportion of participants and whether events were solicited.

    There were more adverse events in the 200‐μg arm than in the placebo or 400‐μg arms as shown in Supplementary Material S1.

    PMID 31211416 · one of two readings recorded this

  • anteroposterior postural sway at 12 months, AMTI AccuSway platform, feet together, eyes open and closed (primary endpoint)

    no effect

    Not recorded as a finding: No outcome node for postural sway, and the sentence names neither vitamin K2 nor an arm. Table 2 gives 200 µg vs placebo −0.19 cm (95% CI −0.68 to 0.30, p = .44) and 400 µg vs placebo 0.17 cm (−0.33 to 0.66, p = .50), baseline-adjusted.

    No significant differences in AP sway were seen between groups at 12 months, either adjusted for baseline or adjusted for minimization variables.

    PMID 31211416 · one of two readings recorded this

  • anteroposterior postural sway at 12 months, AMTI AccuSway sway platform, adjusted for baseline (primary outcome)

    no effect, no significant between-group difference at 12 months, adjusted for baseline or for minimization variables

    Not recorded as a finding: No outcome node for postural sway; the Results sentence is also agentless and does not name the compound.

    No significant differences in AP sway were seen between groups at 12 months, either adjusted for baseline or adjusted for minimization variables.

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, adjusted for baseline

    no effect, p = 0.44

    Adjusted for baseline | 200 μg vs placebo | −.19 (−.68 to.30) |.44

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, adjusted for baseline

    no effect, p = 0.5

    400 μg vs placebo |.17 (−.33 to.66) |.50

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, adjusted for baseline

    no effect, p = 0.14

    200 μg vs 400 μg |.36 (−.11 to.83) |.14

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, fully adjusted

    no effect, p = 0.69

    Fully adjusted a | 200 μg vs placebo | −.09 (−.53 to.35) |.69

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, fully adjusted

    no effect, p = 0.4

    400 μg vs placebo |.19 (−.25 to.63) |.40

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, fully adjusted

    no effect, p = 0.2

    200 μg vs 400 μg |.28 (−.15 to.70) |.20

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, multiple imputation

    no effect, p = 0.39

    Multiple imputation a | 200 μg vs placebo | −.20 (−.66 to.26) |.39

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, multiple imputation

    no effect, p = 0.88

    400 μg vs placebo |.04 (−.44 to.51) |.88

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, multiple imputation

    no effect, p = 0.31

    200 μg vs 400 μg |.24 (−.22 to.67) |.31

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, repeated measures

    no effect, p = 0.72

    Repeated measures a | 200 μg vs placebo | −.07 (−.43 to.30) |.72

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, repeated measures

    no effect, p = 0.66

    400 μg vs placebo | −.08 (−.44 to.28) |.66

    PMID 31211416 · one of two readings recorded this

  • anteroposterior sway at 12 mo, repeated measures

    no effect, p = 0.93

    200 μg vs 400 μg | −.02 (−.37 to.34) |.93

    PMID 31211416 · one of two readings recorded this

  • blood pressure

    no effect

    No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.

    PMID 31211416 · one of two readings recorded this

  • dp-ucMGP

    decreases

    Dp‐ucMGP levels were significantly lower, however, in the 200 μg and 400 μg vitamin K2 groups than in the placebo group

    PMID 31211416 · one of two readings recorded this

  • dp-ucMGP

    decreases

    Dp‐ucMGP levels were significantly lower, however, in the 200 μg and 400 μg vitamin K2 groups than in the placebo group

    PMID 31211416 · one of two readings recorded this

  • dp-ucMGP

    decreases

    confirming that vitamin K was producing the expected dose‐dependent effect on this marker of vitamin K biological activity

    PMID 31211416 · one of two readings recorded this

  • falls rate from monthly falls diaries

    no effect, falls rate not significantly different from placebo; numerically higher in the 200 µg arm

    Not recorded as a finding: No outcome node for falls rate; detailed estimates are only in the supplement.

    The treatment groups did not show a statistically significantly different falls rate to placebo, although falls rates were higher in the 200‐μg arm.

    PMID 31211416 · both readings recorded this

  • falls rate

    no effect

    The treatment groups did not show a statistically significantly different falls rate to placebo, although falls rates were higher in the 200‐μg arm.

    PMID 31211416 · one of two readings recorded this

  • falls rate

    increases

    The treatment groups did not show a statistically significantly different falls rate to placebo, although falls rates were higher in the 200‐μg arm.

    PMID 31211416 · one of two readings recorded this

  • health and social care costs per participant

    increases

    Costs were lowest over 1 year among participants randomized to the placebo group (mean cost = £764 per participant).

    PMID 31211416 · one of two readings recorded this

  • health and social care costs per participant

    decreases

    Costs were lower among participants in the low‐dose vitamin K2 group, relative to high‐dose vitamin K2 (£896‐£902 vs £1033‐£1044).

    PMID 31211416 · one of two readings recorded this

  • incremental costs and quality-adjusted life years (EQ5D-5L) relative to placebo

    neither dose produced any improvement relative to placebo

    Not recorded as a finding: A cost-effectiveness result with no health-related quality-of-life estimate in the text; the sentence negates only one tail ('any improvement').

    Neither dose of vitamin K2 produced any improvement relative to placebo.

    PMID 31211416 · one of two readings recorded this

  • incremental costs and quality-adjusted life years

    no effect

    Neither dose of vitamin K2 produced any improvement relative to placebo.

    PMID 31211416 · one of two readings recorded this

  • Log10 Berg Balance Scale treatment effect at 12 mo

    no effect, p = 0.31

    Log10 Berg Balance Scale treatment effect a (95% CI) | 200 μg vs placebo |.00 (−.00 to.02) |.31

    PMID 31211416 · one of two readings recorded this

  • Log10 Berg Balance Scale treatment effect at 12 mo

    no effect, p = 0.8

    400 μg vs placebo | −.00 (−.02 to.01) |.80

    PMID 31211416 · one of two readings recorded this

  • Log10 Berg Balance Scale treatment effect at 12 mo

    no effect, p = 0.2

    200 μg vs 400 μg | −.01 (−.03 to.00) |.20

    PMID 31211416 · one of two readings recorded this

  • Log10 Timed Up & Go Test treatment effect at 12 mo

    no effect, p = 0.44

    Log10 Timed Up & Go Test treatment effect a (95% CI) | 200 μg vs placebo |.02 (−.03 to.07) |.44

    PMID 31211416 · one of two readings recorded this

  • Log10 Timed Up & Go Test treatment effect at 12 mo

    no effect, p = 0.23

    400 μg vs placebo |.03 (−.02 to.09) |.23

    PMID 31211416 · one of two readings recorded this

  • Log10 Timed Up & Go Test treatment effect at 12 mo

    no effect, p = 0.64

    200 μg vs 400 μg |.01 (−.04 to.06) |.64

    PMID 31211416 · one of two readings recorded this

  • other measures of postural sway

    no effect

    No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.

    PMID 31211416 · one of two readings recorded this

  • other sway measures (mediolateral sway, 95% ellipse, total path length), blood pressure (supine, OMRON HEM-705 oscillometric), and physical performance (Short Physical Performance Battery, Timed Up & Go, Berg Balance Scale)

    no effect, no significant between-group differences

    Not recorded as a finding: No node for sway, SPPB, Timed Up & Go or Berg Balance Scale. Blood pressure was taken supine, and CAT:outcome/office-systolic-blood-pressure requires seated readings. The sentence is agentless and does not name the compound.

    No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.

    PMID 31211416 · one of two readings recorded this

  • other sway measures (mediolateral sway, 95% ellipse, total path length), supine office blood pressure by OMRON HEM-705, Short Physical Performance Battery, Timed Up & Go and Berg Balance Scale

    no effect

    Not recorded as a finding: No node for the sway, SPPB, Timed Up & Go or Berg measures; blood pressure was taken supine, which the office blood pressure nodes (seated) do not admit; and the sentence names neither vitamin K2 nor an arm.

    No significant differences were seen between groups for other measures of sway, for blood pressure, or for measures of physical performance.

    PMID 31211416 · one of two readings recorded this

  • quality-adjusted life years and incremental costs (EQ-5D-5L, ICECAP-O, health and social care costs)

    Not recorded as a finding: The sentence is a one-sided negation about QALYs and cost-effectiveness, not an EQ-5D score, so health-related-quality-of-life cannot be anchored on it.

    Neither dose of vitamin K2 produced any improvement relative to placebo.

    PMID 31211416 · one of two readings recorded this

  • SPPB treatment effect at 12 mo

    no effect, p = 0.63

    SPPB treatment effect a (95% CI) | 200 μg vs placebo | −.2 (−1.1 to.7) |.63

    PMID 31211416 · one of two readings recorded this

  • SPPB treatment effect at 12 mo

    no effect, p = 0.37

    400 μg vs placebo | −.4 (−1.3 to.5) |.37

    PMID 31211416 · one of two readings recorded this

  • SPPB treatment effect at 12 mo

    no effect, p = 0.66

    200 μg vs 400 μg | −.2 (−1.1 to.7) |.66

    PMID 31211416 · one of two readings recorded this

  • time to first fall

    no effect

    Time to first fall was also not significantly different from placebo in the treatment groups.

    PMID 31211416 · one of two readings recorded this

  • unadjusted anteroposterior sway, baseline to 12 mo

    Unadjusted anteroposterior sway, cm (SD) | Placebo | 2.74 (1.01) | 2.84 (1.35) | 2.75 (1.38)

    PMID 31211416 · one of two readings recorded this

  • unadjusted anteroposterior sway, baseline to 12 mo

    Vitamin K 200 μg | 2.95 (.88) | 3.01 (1.33) | 2.51 (1.02)

    PMID 31211416 · one of two readings recorded this

  • unadjusted anteroposterior sway, baseline to 12 mo

    Vitamin K 400 μg | 2.93 (1.21) | 2.67 (1.22) | 2.88 (1.20)

    PMID 31211416 · one of two readings recorded this

  • unadjusted anteroposterior sway, baseline to 6 mo

    Unadjusted anteroposterior sway, cm (SD) | Placebo | 2.74 (1.01) | 2.84 (1.35) | 2.75 (1.38)

    PMID 31211416 · one of two readings recorded this

  • unadjusted anteroposterior sway, baseline to 6 mo

    Vitamin K 200 μg | 2.95 (.88) | 3.01 (1.33) | 2.51 (1.02)

    PMID 31211416 · one of two readings recorded this

  • unadjusted anteroposterior sway, baseline to 6 mo

    Vitamin K 400 μg | 2.93 (1.21) | 2.67 (1.22) | 2.88 (1.20)

    PMID 31211416 · one of two readings recorded this

  • unadjusted Berg Balance Scale (median), baseline to 12 mo

    Unadjusted Berg Balance Scale (median, IQR) | Placebo | 50 [45‐53] | 51 [38‐53] | 52 [41‐54]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Berg Balance Scale (median), baseline to 12 mo

    Vitamin K 200 μg | 48 [42‐53] | 52 [46‐54] | 50 [47‐54]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Berg Balance Scale (median), baseline to 12 mo

    Vitamin K 400 μg | 48 [44‐54] | 47 [42‐54] | 49 [40‐54]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Berg Balance Scale (median), baseline to 6 mo

    Unadjusted Berg Balance Scale (median, IQR) | Placebo | 50 [45‐53] | 51 [38‐53] | 52 [41‐54]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Berg Balance Scale (median), baseline to 6 mo

    Vitamin K 200 μg | 48 [42‐53] | 52 [46‐54] | 50 [47‐54]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Berg Balance Scale (median), baseline to 6 mo

    Vitamin K 400 μg | 48 [44‐54] | 47 [42‐54] | 49 [40‐54]

    PMID 31211416 · one of two readings recorded this

  • unadjusted SPPB, baseline to 12 mo

    Unadjusted SPPB (mean, SD) | Placebo | 7.7 (2.3) | 8.0 (2.7) | 7.9 (3.0)

    PMID 31211416 · one of two readings recorded this

  • unadjusted SPPB, baseline to 12 mo

    Vitamin K 200 μg | 7.4 (2.6) | 7.8 (2.7) | 7.8 (2.7)

    PMID 31211416 · one of two readings recorded this

  • unadjusted SPPB, baseline to 12 mo

    Vitamin K 400 μg | 7.1 (2.7) | 7.2 (2.8) | 6.7 (3.1)

    PMID 31211416 · one of two readings recorded this

  • unadjusted SPPB, baseline to 6 mo

    Unadjusted SPPB (mean, SD) | Placebo | 7.7 (2.3) | 8.0 (2.7) | 7.9 (3.0)

    PMID 31211416 · one of two readings recorded this

  • unadjusted SPPB, baseline to 6 mo

    Vitamin K 200 μg | 7.4 (2.6) | 7.8 (2.7) | 7.8 (2.7)

    PMID 31211416 · one of two readings recorded this

  • unadjusted SPPB, baseline to 6 mo

    Vitamin K 400 μg | 7.1 (2.7) | 7.2 (2.8) | 6.7 (3.1)

    PMID 31211416 · one of two readings recorded this

  • unadjusted Timed Up & Go (median), baseline to 12 mo

    Unadjusted Timed Up & Go (median, IQR) | Placebo | 12.9 [9.7‐17.1] | 9.9 [8.5‐16.2] | 11.2 [9.1‐17.2]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Timed Up & Go (median), baseline to 12 mo

    Vitamin K 200 μg | 14.2 [9.2‐21.3] | 11.7 [8.4‐18.1] | 12.5 [8.9‐19.0]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Timed Up & Go (median), baseline to 12 mo

    Vitamin K 400 μg | 14.1 [9.4‐20.4] | 12.9 [8.4‐17.9] | 13.3 [9.6‐18.7]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Timed Up & Go (median), baseline to 6 mo

    Unadjusted Timed Up & Go (median, IQR) | Placebo | 12.9 [9.7‐17.1] | 9.9 [8.5‐16.2] | 11.2 [9.1‐17.2]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Timed Up & Go (median), baseline to 6 mo

    Vitamin K 200 μg | 14.2 [9.2‐21.3] | 11.7 [8.4‐18.1] | 12.5 [8.9‐19.0]

    PMID 31211416 · one of two readings recorded this

  • unadjusted Timed Up & Go (median), baseline to 6 mo

    Vitamin K 400 μg | 14.1 [9.4‐20.4] | 12.9 [8.4‐17.9] | 13.3 [9.6‐18.7]

    PMID 31211416 · one of two readings recorded this

  • dp-ucMGP concentration

    decreases

    MK-7 supplementation significantly reduced dp-ucMGP compared with placebo (-205.6 pmol/L; 95% CI: -255.8, -155.3 pmol/L)

    PMID 31387121 · one of two readings recorded this

  • femoral arterial calcification, 18F-NaF PET target-to-background ratio; calcification mass on CT

    TBR difference 0.25; 95% CI: -0.02, 0.51, p = 0.06

    Not recorded as a finding: this platform holds no node for the endpoint

    After the 6-mo intervention, TBR tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), although this was not significant.

    PMID 31387121 · one of two readings recorded this

  • femoral arterial calcification, 18F-NaF PET target-to-background ratio

    no effect, p = 0.06

    TBR tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06)

    PMID 31387121 · one of two readings recorded this

  • femoral arterial calcification as 18F-NaF PET target-to-background ratio; CT calcification mass; serum dp-ucMGP

    0.25; 95% CI: -0.02, 0.51, p = 0.06

    Not recorded as a finding: this platform holds no node for the endpoint

    After the 6-mo intervention, TBR tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), although this was not significant.

    PMID 31387121 · one of two readings recorded this

  • log-transformed CT calcification mass

    no effect, p = 0.18

    Log-transformed CT calcification mass did not increase in the intervention group compared with placebo (0.50; 95% CI: -0.23, 1.36; P = 0.18)

    PMID 31387121 · one of two readings recorded this

  • aortic calcification (Agatston score)

    no effect

    Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.

    PMID 31529295 · one of two readings recorded this

  • aortic calcification (Agatston score)

    increases

    Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.

    PMID 31529295 · one of two readings recorded this

  • aortic calcification (Agatston score)

    increases

    Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.

    PMID 31529295 · one of two readings recorded this

  • progression of aortic calcification, Agatston score on abdominal computed tomography at baseline and 12 months; also uncarboxylated MGP (uc-MGP) by ELISA at baseline, 3 and 12 months

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    Agatston score was increased significantly both in vitamin K2 and control group at 1 year with no difference between groups.

    PMID 31529295 · one of two readings recorded this

  • uncarboxylated MGP (uc-MGP) by ELISA at randomization, 3 and 12 months; also aortic calcification by Agatston score on abdominal computed tomography at baseline and 12 months (no between-group difference)

    decreases, significantly lower uc-MGP in the vitamin K2 group than in controls at 1 year, p = 0.03

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    At 1 year, vitK2 group had significantly lower values of uc-MGP in comparison to controls (p = 0.03).

    PMID 31529295 · one of two readings recorded this

  • uncarboxylated MGP (uc-MGP)

    decreases, p = 0.03

    At 1 year, vitK2 group had significantly lower values of uc-MGP in comparison to controls (p = 0.03)

    PMID 31529295 · one of two readings recorded this

  • uncarboxylated MGP (uc-MGP)

    increases

    Furthermore, uc-MGP at 1 year was increased by 12% in the control group.

    PMID 31529295 · one of two readings recorded this

  • uncarboxylated MGP (uc-MGP)

    decreases, p = 0.005

    After 3 months of treatment, uc-MGP values remained unchanged in the vitK2 group but after 1 year were reduced by 47% (p = 0.005)

    PMID 31529295 · one of two readings recorded this

  • uncarboxylated MGP (uc-MGP)

    no effect

    After 3 months of treatment, uc-MGP values remained unchanged in the vitK2 group but after 1 year were reduced by 47% (p = 0.005)

    PMID 31529295 · one of two readings recorded this

  • bone loss

    no effect

    VK2 supplementation in dose of 90 µg/day performed a significant effect on reducing bone loss in postmenopausal women, but in combination with calcium and vitamin D3 brought no additional effects

    PMID 32060566 · one of two readings recorded this

  • cOC/ucOC ratio

    increases, p = 0.001

    Serum biomarkers cOC/ucOC ratio increased in the intervention groups (treatment × time, p < 0.001)

    PMID 32060566 · one of two readings recorded this

  • femoral neck bone loss (BMD change) after 1 year, men and postmenopausal women analysed separately; serum carboxylated/undercarboxylated osteocalcin (cOC/ucOC) ratio

    decreases, femoral neck bone loss lower in postmenopausal women in the two 90 µg groups pooled vs placebo (treatment × time p = 0.006); no effect in men, p = 0.006

    Not recorded as a finding: the paper never mentions the compound

    At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men.

    PMID 32060566 · one of two readings recorded this

  • femoral neck bone loss (bone mineral density) over 1 year, measuring instrument not named in the abstract; also serum cOC/ucOC ratio

    decreases, femoral neck bone loss significantly lower than placebo in postmenopausal women in the two 90 µg groups (treatment x time p = 0.006); no effect in men (subgroup result), p = 0.006

    Not recorded as a finding: the paper never mentions the compound

    At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men.

    PMID 32060566 · one of two readings recorded this

  • femoral neck bone loss

    no effect

    At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men

    PMID 32060566 · one of two readings recorded this

  • femoral neck bone loss

    decreases, p = 0.006

    At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 µg groups (treatment × time, p = 0.006) compared with placebo, but no effects in men

    PMID 32060566 · one of two readings recorded this

The whole record — 417 rows